Affiliation:
1. National Research Center for Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health of the Russian Federation, Moscow, 123098, Russia
Abstract
Bifidobacteria occupy a special place among various representatives of normal human microbiota. A wide range of probiotic preparations has been obtained based on cultivated strains of various bifidobacteria of the intestinal microbiota. A number of scientific publications noted the immunomodulatory, anticarcinogenic, and antiviral properties of bifidobacteria in vitro and in vivo. Recently, progress has been made in the research and application of this group of microorganisms in genetic engineering. It was established that vaccines against viral and bacterial infections and antitumor substances can be developed on the basis of various strains of bifidobacteria. Bifidobacteria can also be used as adjuvants for other vaccines, as well as delivery systems for biologically active substances to tumors. The prospects for the use of bifidobacteria for the development of recombinant vaccines are discussed.
bifidobacteria, medical and biological properties, recombinant vaccines, drug delivery, adjuvants, plasmids
This work was funded by the Epidemiology and Microbiology National Research Center.
The authors are grateful to V. V. Kuprianov for valuable comments on the text of the review.
Publisher
National Research Center Kurchatov Institute
Subject
Ecology,Applied Microbiology and Biotechnology,Biotechnology
Reference39 articles.
1. Bondarenko V.M. The role of opportunistic bacteria in chronic inflammatory processes of various localization. Tver: Triada. 88 p..
2. 2. Shenderov B.A., Manvelova M.A Functional nutrition and probiotics: microecological aspects. Moscow: Agar, 1997, 23 p..
3. 3. Majdannik V.G. Probiotics: prospects for use in childhood. Int J Pediatr, Obstetr Gynecol. 2013, 4(3), 62-80.
4. 4. Sadiq F.A. Is it time for microbiome-based therapies in viral infection? Virus Res., 2021, 291:198203. doi 10.1016/j.virusres.2020.198203
5. 5. Rush K., Rush F. Microbiological therapy. M.: Arnebia. 2003, 108 p.